Erianin

Erianin is an inhibitor of TDO and IDO1 used in studies of Immune Signaling. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to cytokine-mediated signaling and inflammatory effector responses in angiogenesis, cancer, and immunology models.

By inhibiting TDO and IDO1, Erianin can be used to examine cytokine-mediated signaling and inflammatory effector responses. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, cancer, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving TDO and IDO1
• Pathway perturbation studies connected to Immune Signaling
• Concentration-response inhibition and target-dependence studies
• Enzyme-activity assays, substrate-conversion studies, and mechanism profiling

Overall, Erianin is appropriate when a defined chemical perturbant is needed to connect TDO and IDO1 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, cancer, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.